

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
27 September 2007 (27.09.2007)

PCT

(10) International Publication Number  
**WO 2007/108749 A8**(51) International Patent Classification:  
*C07K 19/00* (2006.01) *C07K 7/06* (2006.01)  
*A61K 47/48* (2006.01)**Lianglin** [CN/US]; Department of Intellectual Property Management, Burnham Institute For Medical Research, 10901 N. Torrey Pines Road, La Jolla, California 92037 (US).(21) International Application Number:  
PCT/SE2007/000268(74) Agent: **ZACCO SWEDEN AB**; P.O. Box 23101, S-104 35 Stockholm (SE).(22) International Filing Date:  
20 March 2007 (20.03.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/783,396 20 March 2006 (20.03.2006) US(71) Applicants (for all designated States except US): **CEPEP III AB** [SE/SE]; PO Box 45029, S-104 30 Stockholm (SE). **BURNHAM INSTITUTE FOR MEDICAL RESEARCH** [US/US]; 10901 N. Torrey Pines Road, La Jolla, California 92037 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(72) Inventors; and

(75) Inventors/Applicants (for US only): **LANGEL, Ülo** [SE/SE]; Karlbergsvägen 46B, S-113 37 Stockholm (SE). **MYRBERG, Helena** [SE/SE]; Tulegatan 32A, S-113 53 Stockholm (SE). **MÄE, Maarja** [EE/SE]; Kungshamra 81-114, S-170 70 Solna (SE). **RUOSLAHTI, Erkki** [US/US]; Department of Intellectual Property Management, Burnham Institute for Medical Research, 10901 N. Torrey Pines Road, La Jolla, California 92037 (US). **ZHANG,**

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: CHIMERIC CONSTRUCTS BETWEEN CANCER-HOMING PEPTIDES AND CELL-PENETRATING PEPTIDES COUPLED TO ANTICANCER DRUGS AND/OR DIAGNOSTIC AGENT/AGENTS



(57) Abstract: A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3 - SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell comprising administration of a construct according to the invention in vivo or in vitro is described.

WO 2007/108749 A8



---

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

**(48) Date of publication of this corrected version:**

13 August 2009

**(15) Information about Correction:**

see Notice of 13 August 2009